Mofezolac
- CAS No.
- 78967-07-4
- Chemical Name:
- Mofezolac
- Synonyms
- N-22;Disopain;Mofezolac;Mofezolac, 10 mM in DMSO;3,4-Bis(4-methoxyphenyl)isoxazole-5-acetic acid;3,4-Bis(4-methoxyphenyl)-5-isoxazoleacetic acid;5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)-;2-(3,4-bis(4-Methoxyphenyl)isoxazol-5-yl)acetic acid;α-[3,4-Bis(4-methoxyphenyl)-5-isoxazolyl]acetic acid;2-[3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]acetic acid
- CBNumber:
- CB7875698
- Molecular Formula:
- C19H17NO5
- Molecular Weight:
- 339.34
- MDL Number:
- MFCD00712149
- MOL File:
- 78967-07-4.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Melting point | 147.5℃ |
|---|---|
| Boiling point | 527.2±50.0 °C(Predicted) |
| Density | 1.250±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO: soluble |
| form | A solid |
| pka | pKa ~3.3(at 25℃) |
| color | White to off-white |
| FDA UNII | RVJ0BV3H3Y |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H317-H319 | |||||||||
| Precautionary statements | P280-P305+P351+P338 | |||||||||
| Toxicity | LD50 in male, female mice, male, female rats (mg/kg): 1528, 1740, 920, 887 orally; 275, 321, 378, 342 i.p.; 612, 545, 572, 510 s.c. (Satoh) | |||||||||
| NFPA 704 |
|
Mofezolac price More Price(36)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | R678899 | (3,4-BIS(4-METHOXYPHENYL)-5-ISOXAZOLYL)ACETIC ACID AldrichCPR | 78967-07-4 | 1 unit | $197 | 2026-04-30 | Buy |
| Sigma-Aldrich | R678899 | (3,4-BIS(4-METHOXYPHENYL)-5-ISOXAZOLYL)ACETIC ACID AldrichCPR | 78967-07-4 | 25MG | $179 | 2024-03-01 | Buy |
| Cayman Chemical | 34102 | Mofezolac ≥98% | 78967-07-4 | 5mg | $49 | 2026-04-30 | Buy |
| Cayman Chemical | 34102 | Mofezolac ≥98% | 78967-07-4 | 10mg | $87 | 2026-04-30 | Buy |
| Cayman Chemical | 34102 | Mofezolac ≥98% | 78967-07-4 | 25mg | $194 | 2026-04-30 | Buy |
Mofezolac Chemical Properties,Uses,Production
Description
Mofezolac is a new non-steroidal analgesic antiinflammatory agent introduced in Japan for the treatment of post-operative and post-traumatic pain, acute upper respiratory tract pain, osteoarthritis, and lumbago. In in vfim studies, mofezolac inhibits prostaglandin biosynthesis and platelet aggregation, reportedly through the inhibition of cyclooxygenase. In animal studies, mofezolac showed more potent suppression in various writhing models than agents such as ibuprofen, mefenamic acid and aspirin. Mofezolac also has a potent inhibitory activity on the algesic responses induced by the mechanical stimulus of the inflamed tissue. The ulcerogenic effect of mofezolac on the gastric mucosa is far weaker than that of indomethacin and other agents.
Originator
Pasteur Merieux (France)
Definition
ChEBI: Mofezolac (TN) is a member of methoxybenzenes.
brand name
Disopain
Clinical Use
Yoshitomi (now Mitsubishi Pharma) has launched mofezolac, a COX-1 inhibitor with preferential COX-1 inhibition for the treatment of arthritis-related pain in Japan. The compound is used in oral doses of 75mg for the treatment of periarthritis, lumbago, neckshoulder- arm syndrome and pain after surgery, trauma, or dental extraction.
Synthesis
The reaction of deoxyanisoin with hydroxylamine
in methanol gives the corresponding
1,2-bis(4-methoxyphenyl)ethanone oxime,
which is cyclized with ethyl acetate by means
of n-butyllithium in tetrahydrofuran yielding
3,4-di(4-methoxyphenyl)-5-methylisoxazole.
Finally, this compound is condensed
with CO2 with n-butyllithium as catalyst
in tetrahydrofuran to yield mofezolac . The synthesis with ClCO2C2H5 instead
of CO2 is described in .
Mofezolac Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Chembest Research Laboratories Limited | 021-20908456 | sales@BioChemBest.com | China | 5996 | 61 |
| Acorn PharmaTech Co., Ltd. | 025-58395930 | sales@acornpharma.com | China | 982 | 60 |
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 18149758185 | sales-cpd@caerulumpharma.com | China | 3493 | 58 |
| Shanghai JiYi Biotechnology Co. Ltd. | 13621943973 | sales@shjiyipharmatech.com | China | 1166 | 55 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Shanghai Chaolan Chemical Technology Center | QQ：65489617 13301690235 | Sales@ATKchemical.com | China | 9699 | 58 |
| Amadis Chemical Company Limited | 571-89925085 | sales@amadischem.com | China | 131885 | 58 |
| Aikon International Limited | 025-58859352 15955137747 | sales01@aikonchem.com | China | 16021 | 58 |
| BOC Sciences | 16314854226; +8616314854226 | inquiry@bocsci.com | United States | 19852 | 58 |
